UNSPSC 51101916: Amopyroquine

This classification denotes an antimalarial agent with the molecular formula C20H20ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SV6L22Y9QF, chemically known as 4-((7-chloro-4-quinolyl)amino)-alpha-1-pyrrolidinyl-o-cresol or 4-[(7-chloranylquinolin-4-yl)amino]-2-(pyrrolidin-1-ylmethyl)phenol, but generally known as amopyroquine, which bears US NIH Compound Identifier 25194. European Medicines Agency schedules amopyroquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05475MIG.

Most nations schedule amopyroquine under HS 29334990 and SITC 51575. As of Q4 2014, AMOPYROQUINE remains the US FDA Preferred Term for this commodity. Amopyroquine bears US NLM identifiers UMLS ID C0051735 and NCI Concept Code C73000. SMILES: C1CCN(C1)CC2=C(C=CC(=C2)NC3=C4C=CC(=CC4=NC=C3)Cl)O.

UNSPSC 51101916 Amopyroquine, a Commodity code, does not reflect the recent state and local procurement activity tagged under it. The two most recent opportunities posted under this code involve Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets (Illinois Department of Public Health, August 2026) and Naloxone with Safe Drug Deactivation Systems (Seminole County, Florida, June 2026) — neither of which is Amopyroquine. The mismatch suggests that state and local procurement offices are using this code as a catch-all or placeholder for pharmaceutical commodities outside the specific drug name the code nominally describes, or that the tagging does not reflect the actual scope of work. State and local health departments and county public health programs appear to be the primary issuing bodies using this code for pharmaceutical procurement, typically through cooperative purchasing vehicles such as MMCAP Infuse or direct competitive bidding.

Activity is concentrated in Illinois and Florida based on recent postings. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract to Chartwell Rx LLC on August 28, 2026, for a 12-month initial term with two renewal options, while Seminole County, Florida solicited an IFB for annual Naloxone and drug deactivation systems with quarterly deliveries on a two-year term plus one-year renewal option (due July 26, 2023). Given the divergence between the code's nominal scope and the actual commodities being procured, business development professionals should verify code alignment with their target product before investing pursuit effort — the code may not be a reliable indicator of Amopyroquine demand in state and local markets.